Cargando…

Personalized circulating tumor DNA detection to monitor immunotherapy efficacy and predict outcome in locally advanced or metastatic non‐small cell lung cancer

OBJECTIVE: Immune checkpoint inhibitors (ICIs) or combined with chemotherapy exhibit substantial efficacy for the treatment of advanced non‐small cell lung cancer (NSCLC). However, reliable biomarkers that can monitor response to first‐line ICIs ± chemotherapy remain unclear. METHODS: A total of 16...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheng, Lei, Gao, Guanghui, Zhao, Chao, Wang, Haowei, Yao, Chao, Yu, Hanchuanzhi, Yao, Jichen, Li, Feng, Guo, Lijie, Jian, Qijie, Chen, Xiaoxia, Li, Xuefei, Zhou, Caicun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10358227/ https://www.ncbi.nlm.nih.gov/pubmed/37184093 http://dx.doi.org/10.1002/cam4.6108

Ejemplares similares

Interleukin-10 Is a Promising Marker for Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer Receiving Immunotherapy
por: Wang, Haowei, et al.
Publicado: (2022)

The Role of Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Wang, Haowei, et al.
Publicado: (2021)

Folate receptor-positive circulating tumor cells as a predictive biomarker for the efficacy of first-line pemetrexed-based chemotherapy in patients with non-squamous non-small cell lung cancer
por: Chen, Xiaoxia, et al.
Publicado: (2020)

Outcome differences between PD-1/PD-L1 inhibitors-based monotherapy and combination treatments in NSCLC with brain metastases
por: Wang, Haowei, et al.
Publicado: (2023)

TIM-3, a promising target for cancer immunotherapy
por: He, Yayi, et al.
Publicado: (2018)

The safety and efficacy of immunotherapy with anti-programmed cell death 1 monoclonal antibody for lung cancer complicated with Mycobacterium tuberculosis infection
por: Shi, Jinpeng, et al.
Publicado: (2021)

Predictive and prognostic value of folate receptor-positive circulating tumor cells in small cell lung cancer patients treated with first-line chemotherapy
por: Shen, Jiqiao, et al.
Publicado: (2017)

Interleukin-10 induces expression of CD39 on CD8+T cells to potentiate anti-PD1 efficacy in EGFR-mutated non-small cell lung cancer
por: Qiao, Meng, et al.
Publicado: (2022)

Correlation between thymidylate synthase gene polymorphisms and efficacy of pemetrexed in advanced non-small cell lung cancer
por: HU, QIONG, et al.
Publicado: (2012)

Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China
por: Li, Xuefei, et al.
Publicado: (2016)

Clinical features and therapeutic options in non‐small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF
por: Zhuang, Xibin, et al.
Publicado: (2019)

Association of CD8 T cell apoptosis and EGFR mutation in non‐small lung cancer patients
por: Zhao, Chao, et al.
Publicado: (2020)

The impact of EGFR exon 19 deletion subtypes on clinical outcomes in non-small cell lung cancer
por: Zhao, Chao, et al.
Publicado: (2020)

Detecting ALK, ROS1 and RET Fusion Genes in Cell Block Samples()()
por: Zhao, Chao, et al.
Publicado: (2014)

Soluble PD-L1 as a Predictor of the Response to EGFR-TKIs in Non-small Cell Lung Cancer Patients With EGFR Mutations
por: Jia, Yijun, et al.
Publicado: (2020)

Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring BRAF mutations
por: Wang, Haowei, et al.
Publicado: (2023)

The Association between COX-2 Polymorphisms and Hematologic Toxicity in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Platinum-Based Chemotherapy
por: Zhou, Fei, et al.
Publicado: (2013)

Efficacy of immune-checkpoint inhibitors in advanced non-small cell lung cancer patients with different metastases
por: Qiao, Meng, et al.
Publicado: (2021)

Comparison of cross-platform technologies for EGFR T790M testing in patients with non-small cell lung cancer
por: Li, Xuefei, et al.
Publicado: (2017)

Comprehensive evaluation of NT5E/CD73 expression and its prognostic significance in distinct types of cancers
por: Jiang, Tao, et al.
Publicado: (2018)

Single-Cell Profiling of Tumor-Associated Neutrophils in Advanced Non-Small Cell Lung Cancer
por: Shi, Jinpeng, et al.
Publicado: (2023)

Immune checkpoint inhibitors plus chemotherapy in patients with locally advanced or metastatic pulmonary sarcomatoid carcinoma: a multicentric real-world study
por: Zhou, Fei, et al.
Publicado: (2022)

PD-1/PD-L1 Inhibitor Combined with Chemotherapy Can Improve the Survival of Non-Small Cell Lung Cancer Patients with Brain Metastases
por: Sun, Chenglong, et al.
Publicado: (2020)

Association between Single Nucleotide Polymorphisms (SNPs) and Toxicity of Advanced Non-Small-Cell Lung Cancer Patients Treated with Chemotherapy
por: Zhang, Ling, et al.
Publicado: (2012)

Clinicopathologic characteristics and outcomes of Chinese patients with non‐small‐cell lung cancer and BRAF mutation
por: Ding, Xi, et al.
Publicado: (2017)

Pan-cancer analysis of ARID1A Alterations as Biomarkers for Immunotherapy Outcomes
por: Jiang, Tao, et al.
Publicado: (2020)

Quantitative monitoring of circulating tumor DNA predicts response of cutaneous metastatic melanoma to anti-PD1 immunotherapy
por: Herbreteau, Guillaume, et al.
Publicado: (2018)

Circulating protein and antibody biomarker for personalized cancer immunotherapy
por: Yuan, Jianda
Publicado: (2016)

Local tumour hyperthermia as immunotherapy for metastatic cancer
por: Toraya-Brown, Seiko, et al.
Publicado: (2014)

Peripheral Blood for Epidermal Growth Factor Receptor Mutation Detection in Non-Small Cell Lung Cancer Patients
por: Li, Xuefei, et al.
Publicado: (2014)

Effect of chemotherapy alone or combined with immunotherapy for locally advanced or metastatic genitourinary small cell carcinoma: a real-world retrospective study
por: Huang, Riqing, et al.
Publicado: (2023)

Sequential Circulating Tumor Cell Counts in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: Monitoring the Treatment Response
por: Rau, Kun-Ming, et al.
Publicado: (2020)

MiR-200c overexpression is associated with better efficacy of EGFR-TKIs in non-small cell lung cancer patients with EGFR wild-type
por: Li, Jiayu, et al.
Publicado: (2014)

Exosomes transmit T790M mutation‐induced resistance in EGFR‐mutant NSCLC by activating PI3K/AKT signalling pathway
por: Liu, Xiaozhen, et al.
Publicado: (2020)

Treatment of spine metastases in cancer: a review
por: Chen, Yu, et al.
Publicado: (2019)

High discrepancy in thrombotic events in non-small cell lung cancer patients with different genomic alterations
por: Liu, Yiwei, et al.
Publicado: (2021)

Long non-coding RNA UCA1 induces non-T790M acquired resistance to EGFR-TKIs by activating the AKT/mTOR pathway in EGFR-mutant non-small cell lung cancer
por: Cheng, Ningning, et al.
Publicado: (2015)

Circulating tumor DNA for personalized lung cancer monitoring
por: Fiala, Clare, et al.
Publicado: (2017)

Spatial multi-omics revealed the impact of tumor ecosystem heterogeneity on immunotherapy efficacy in patients with advanced non-small cell lung cancer treated with bispecific antibody
por: Song, Xinyu, et al.
Publicado: (2023)

Monitoring PD-L1 Expression on Circulating Tumor–Associated Cells in Recurrent Metastatic Non–Small-Cell Lung Carcinoma Predicts Response to Immunotherapy With Radiation Therapy
por: Moran, Jillian A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_f6b1jult6qupoedogp7ir4ghah